dacarbazine,doxorubicin,brentuximab vedotin,vinblastine,bleomycin,vincristine
seagen
['kudos']
hd21 trial of brecadd with pet adaptation vs ebeacopp; showing non-inferiority, 15% rt rate, with mature follow up time; kudos for a study accrual of 1500 pts! this is certainly a year of food for thought in chl among all the new data vying for practice-changing data! #17icml 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.